NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Apollo Therapeutics

Apollo Therapeutics

Private
CambridgeHealthcare & Life Scienceshttps://www.apollotx.com/

Last Round

Series C

Jan 2, 2024

Est. Valuation

$246.75M

Total Funding Raised

$722M

Company Overview

Apollo Therapeutics is a biopharmaceutical company that translates fundamental medical research into innovative medicines by developing a diverse portfolio of pre-clinical and clinical-stage assets in oncology, inflammatory disorders, and rare diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoverybiotechclinical-stagetherapeutic developmentacademic partnershipsdrug pipelinetranslational researchbiotech incubatorasset licensingvalley of deathr&d pipelinebiotech hub

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Apollo Therapeutics Comparables

Compare Apollo Therapeutics with similar companies based on industry and business-model similarity.

Apollo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Orange Grove Bio
77%
Eli Lilly and Company
77%
PureTech Health
70%

Apollo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 2, 2024
Series C ExtensionDec 1, 2023
Series CSep 6, 2023
Series BJun 17, 2021
SeedJan 25, 2016

Key People

Founding team and executive leadership

Jamie Heath

Chief Financial Officer

Executive Team

Apollo Therapeutics Investors

Notable investors and investment history

Apollo Therapeutics investors
InvestorRounds
IP GroupSeries B
Patient Square CapitalSeries C Extension, Series C, Series B
Reimagined VenturesSeries B
Imperial College LondonSeed
M&G InvestmentsSeries C
Imperial InnovationsSeed
University College LondonSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 5, 2025

    Developing a monoclonal antibody treatment for pulmonary arterial hypertension (PAH).

  • May 5, 2025

    Collaborating with Imperial College London on new antibody treatment.

Apollo Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Apollo Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Apollo Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range66
Year Founded2016
Last FundingJan 2, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.